The FDA has approved Adzenys XR-ODT (amphetamine extended release oral), from Neos Therapeutics, for the treatment of ADHD in patients...
Neos Therapeutics, Inc. has announced that the FDA approved Cotempla XR-ODT, the first and only methylphenidate extended-release orally disintegrating tablet...
Neos Therapeutics has resubmitted a New Drug Application to the FDA for its amphetamine XR orally disintegrating tablet product candidate,...
Neos Therapeutics has announced the presentation of new data from a clinical trial of orally disintegrating tablet Cotempla XR-ODT (extended...
Biohaven Pharmaceutical and Pfizer Inc. announced positive top-line results from an Asia-Pacific, Phase III clinical trial of Nurtec ODT (rimegepant) in 1,431 adults for the acute treatment of migraine.
Adults: Zofran tablets are indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. Zofran tablets are indicated for the prevention of post-operative nausea and vomiting (PONV). For treatment of established PONV, administration by injection is recommended. Paediatric Population: Zofran is indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in children aged ≥6 months. No studies have been conducted on the use of orally administered ondansetron in the prevention and treatment of PONV in children aged ≥1 month, administration by IV injection is recommended for this purpose.